Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo

Pharmacology, Biochemistry, and Behavior
C A BriggsS P Arneric

Abstract

(2.4)-Dimethoxybenzylidene anabaseine dihydrochloride (GTS-21), a compound that interacts with rat neuronal nicotinic acetylcholine receptors (nAChRs), was evaluated using human recombinant nAChRs in vitro and various pharmacokinetic and behavioral models in rodents, dogs and monkeys. GTS-21 bound to human alpha 4 beta 2 nAChR (K1-20 nM) 100-fold more potently than to human alpha 7 nAChR, and was 18- and 2-fold less potent than (-)-nicotine at human alpha 4 beta 2 and alpha 7 nAChR, respectively. Functionally. GTS-21 stimulated [5H]dopamine release from rat striatal slices with an EC50 of 10 +/- 2 microM (250-fold less potent and 70% as efficacious as (-)-nicotine), an effect blocked by the nAChR antagonist dihydro-beta-erythroidine. However, GTS-21 did not stimulate human alpha 4 beta 2 nor human ganglionic nAChRs significantly. In vivo, GTS-21 had no adverse effect on dog blood pressure (< or = 2.5 micromol/kg i.v. bolus infusion), in marked contrast with (-)-nicotine, GTS-21 (-62 micromol/kg.s.e.) also did not cross-discriminate significantly with (-)-nicotine in rats and did not reduce temperature or locomotion in mice. Neither was it active in the elevated plus maze anxiety model (0.19-6.2 micromol/kg.IP) in normal mice. H...Continue Reading

References

Nov 1, 1992·Trends in Pharmacological Sciences·P B Clarke
Feb 14, 1992·Brain Research·M W DeckerD J Anderson
Jan 1, 1991·Trends in Pharmacological Sciences·E S DenerisR Duvoisin
Jun 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·B SahakianD Warburton
Mar 1, 1983·American Journal of Medical Genetics·P S Moorhead, A Heyman
Dec 1, 1981·Annals of Neurology·L J ThalH Crystal
Mar 11, 1995·Lancet·K L Davis, P Powchik
Jun 1, 1995·Neuropharmacology·J L Galzi, J P Changeux
Jun 1, 1995·Neuropharmacology·C A BriggsM Piattoni-Kaplan
Aug 15, 1995·European Journal of Pharmacology·M GopalakrishnanJ P Sullivan
Jan 23, 1995·Behavioural Brain Research·F J Hock
Jan 1, 1995·Medicinal Research Reviews·I P StolermanM Shoaib
Apr 18, 1994·Brain Research·J D BrioniM W Decker
Jul 6, 1993·European Journal of Pharmacology·J D BrioniM W Decker
Aug 1, 1993·Pharmacology, Biochemistry, and Behavior·A V TerryW J Jackson
Dec 1, 1991·Trends in Cardiovascular Medicine·N L Benowitz

❮ Previous
Next ❯

Citations

Apr 28, 2004·Psychopharmacology·Simon N KatnerMichael A Taffe
Aug 3, 2005·Cellular and Molecular Neurobiology·John W Daly
Jun 8, 2007·Cellular and Molecular Neurobiology·Enrique L M Ochoa, Jose Lasalde-Dominicci
Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Jerry J Buccafusco
Jun 11, 2005·Trends in Pharmacological Sciences·Jerry J BuccafuscoPatrick M Lippiello
Apr 20, 2000·European Journal of Pharmacology·F ClementiC Gotti
Oct 9, 1999·Pharmacology, Biochemistry, and Behavior·F van HaarenW R Kem
Aug 15, 2000·Behavioural Brain Research·N BelluardoK Fuxe
Aug 15, 2000·Behavioural Brain Research·C GottiF Clementi
Aug 19, 2007·The Journal of Physical Chemistry. B·Haiting LuChang-Guo Zhan
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Carrie K JonesMichael Bubser
Apr 28, 2001·British Journal of Pharmacology·F J MiaoJ D Levine
Aug 17, 2002·British Journal of Pharmacology·Roger L Papke, Julia K Porter Papke
Aug 29, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Philippe PichatBernard Scatton
Aug 2, 2002·Neuroreport·Marina R PicciottoBarbara J Caldarone
Feb 19, 2009·The Journal of Pharmacology and Experimental Therapeutics·Roger L PapkeNicole A Horenstein
Mar 4, 2011·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Greg J NormanA Courtney Devries
Jan 5, 2002·Expert Opinion on Investigational Drugs·M W DeckerJ P Sullivan
Apr 23, 2011·Expert Opinion on Investigational Drugs·Niels PlathJohn Paul Redrobe
Sep 1, 2007·Expert Opinion on Drug Discovery·Pm LippielloAa Mazurov
Jul 5, 2005·Expert Opinion on Investigational Drugs·R J ChorvatB S Brown
Nov 28, 2012·Brain Research Bulletin·Balázs LendvaiZsolt Némethy
Aug 29, 2012·Pharmacology & Therapeutics·Raymond HurstDaniel Bertrand
Mar 23, 2011·Pharmacology, Biochemistry, and Behavior·Segev Barak, Ina Weiner
Mar 10, 2010·Brain Research·Earl J GubbinsJinhe Li
Dec 27, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Amir H RezvaniEdward D Levin
Sep 4, 2015·Medicinal Research Reviews·Rongshi Li
Aug 24, 2007·Biochemical Pharmacology·Ann Olincy, Karen E Stevens

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.